Pathophysiologie und Therapie der Osteogenesis imperfecta

O. Semler; M. Rehberg; H. Hoyer-Kuhn

doi:10.1055/s-0038-1676922

Osteologie, Table of Contents

Osteologie 2018; 27(04): 194-199
DOI: 10.1055/s-0038-1676922

Seltene Knochenerkrankungen – Rare bone diseases

Georg Thieme Verlag KG Stuttgart · New York

Pathophysiologie und Therapie der Osteogenesis imperfecta

Pathophysiology and treatment in Osteogenesis imperfecta

O. Semler

¹Klinik für Kinder- und Jugendmedizin, Uniklinik Köln

,

M. Rehberg

¹Klinik für Kinder- und Jugendmedizin, Uniklinik Köln

,

H. Hoyer-Kuhn

¹Klinik für Kinder- und Jugendmedizin, Uniklinik Köln

› Author Affiliations

Abstract

Zusammenfassung

Die Osteogenesis imperfecta (OI) ist die häufigste angeborene Skeletterkrankung im Kindes- und Jugendalter. Sie beruht in den meisten Fällen auf Mutationen, die die Kollagensynthese beeinträchtigen. Bei sehr unterschiedlichen Verlaufsformen besteht keine klare Genotyp-Phänotyp-Korrelation. Führendes Symptom sind rezidivierende Frakturen bei inadäquaten Traumata, aber auch extra-skelettale Symptome wie eine Muskelhypotonie oder Schwerhörigkeit gehören dazu. Die Therapie beinhaltet orthopädisch/chirurgische Maßnahmen zur Frakturversorgung und Korrektur von Deformierungen. Die medikamentöse Behandlung beschränkt sich im Kindesalter auf antiresorptive Medikamente wie Bisphosphonate oder das in Erprobung befindliche Denosumab. Nach Ende des Wachstums werden auch osteoanabole Medikamente eingesetzt. Wichtigste Maßnahme zur Anregung des Knochenaufbaus ist die Kräftigung der Muskulatur durch Physiotherapie und Rehabilitation. Um diese Maßnahmen auf einander abzustimmen und Erfahrungen für weitere Therapieverbesserungen zu sammeln, sollte die Behandlung dieser Patienten in spezialisierten Zentren erfolgen.

Summary

Osteogenesis imperfecta (OI) is the most frequent hereditary bone disease during childhood. In most cases OI is caused by mutations affecting collagen production. Phenotypes of patients differ substantially and there is no clear genotype-phenotype correlation. Main symptom is an increased fracture rate due to inadequate traumata. Additionally, extra-skelettale signs like muscle hypotonia and hearing impairments are frequently reported. The multimodular therapy includes surgical procedures to treat fractures and to correct deformities. During childhood drug therapy is limited to the use of bisphosphonates. Other antiresorptive drugs like Denosumab are currently under investigation. After end of growth osteoanabolic agents like Teriparatide or Antisclerostin can be used. Most important is a regular training including physiotherapy and rehabilitation. To coordinate these therapies the care of the patients need to be centralized. Such a treatment in specialized centers will allow to learn more about natural history of the disease and to improve the care.

Schlüsselwörter

Osteogenesis imperfecta - Therapie - Pathophysiologie - Bisphosphonate

Keywords

Osteogenesis imperfecta - therapy - pathophysiology - bisphosphonates

Full Text

References

Literatur
1 Hoyer-Kuhn H, Bartz-Seel J, Blickheuser R. et al. Diagnostik und Therapie der Osteogenesis imperfecta. Monatsschrift Kinderheilkunde 2016; 165: 333-346.
2 Marini JC, Forlino A, Bachinger HP. et al. Osteogenesis imperfecta. Nat Rev Dis Primers 2017; 03: 17052.
3 Boyde A, Travers R, Glorieux FH, Jones SJ. The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif Tissue Int 1999; 64: 185-190.
4 Schramm T, Gloning KP, Minderer S. et al. Prenatal sonographic diagnosis of skeletal dysplasias. Ultrasound Obstet Gynecol 2009; 34: 160-170.
5 Kidszun A, Linebarger J, Walter JK. et al. What If the prenatal diagnosis of a lethal anomaly turns out to be wrong?. Pediatrics 2016; 137.
6 Pontz BF, Stoss H, Spranger J. Heterogeneity in osteogenesis imperfecta: clinical and morphological findings. Ann N Y Acad Sci 1988; 543: 30-39.
7 Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363: 1377-1385.
8 Andersson K, Dahllof G, Lindahl K. et al. Mutations in COL1A1 and COL1A2 and dental aberrations in children and adolescents with osteogenesis imperfecta – A retrospective cohort study. PLoS One 2017; 12: e0176466.
9 Kuurila K, Grenman R, Johansson R, Kaitila I. Hearing loss in children with osteogenesis imperfecta. Eur J Pediatr 2000; 159: 515-519.
10 Kuurila K, Kaitila I, Johansson R, Grenman R. Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. Ann Otol Rhinol Laryngol 2002; 111: 939-946.
11 Al-Senaidi KS, Ullah I, Javad H, Al-Khabori M, Al-Yaarubi S. Echocardiographic Evidence of Early Diastolic Dysfunction in Asymptomatic Children with Osteogenesis Imperfecta. Sultan Qaboos Univ Med J 2015; 15: e456-e462.
12 Folkestad L, Hald JD, Gram J. et al. Cardiovascular disease in patients with osteogenesis imperfecta – a nationwide, register-based cohort study. Int J Cardiol 2016; 225: 250-257.
13 Forlino A, Marini JC. Osteogenesis imperfecta. Lancet 2016; 387: 1657-1671.
14 Rauch F, Husseini A, Roughley P, Glorieux FH, Moffatt P. Lack of circulating pigment epitheliumderived factor is a marker of osteogenesis imperfecta type VI. J Clin Endocrinol Metab 2012; 97: E1550-E1556.
15 Becker J, Semler O, Gilissen C. et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2011; 88: 362-371.
16 Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr 2006; 148: 456-460.
17 Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998; 87: 64-68.
18 Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-952.
19 Gatti D, Antoniazzi F, Prizzi R. et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20: 758-763.
20 Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2012; 25: 485-491.
21 Bishop N, Adami S, Ahmed SF. et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382: 1424-1432.
22 Sarraf KM. Images in clinical medicine. Radiographic zebra lines from cyclical pamidronate therapy. N Engl J Med 2011; 365: e5.
23 Hoyer-Kuhn H, Franklin J, Allo G. et al. Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial. J Musculoskelet Neuronal Interact 2016; 16: 24-32.
24 Simm PJ, Biggin A, Zacharin MR. et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health 2018; 54: 223-233.
25 Smith-Bindman R, Steiger P, Cummings SR, Genant HK. The index of radiographic area (IRA): a new approach to estimating the severity of vertebral deformity. Bone Miner 1991; 15: 137-149.
26 Sumnik Z, Land C, Rieger-Wettengl G, Korber F, Stabrey A, Schoenau E. Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry. Horm Res 2004; 61: 137-142.
27 Koerber F, Schulze UUphoff, Koerber S, Schonau E, Maintz D, Semler O. Introduction of a new standardized assessment score of spine morphology in osteogenesis imperfecta. Rofo 2012; 184: 719-725.
28 Orwoll ES, Shapiro J, Veith S. et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 2014; 124: 491-498.
29 Gatti D, Rossini M, Viapiana O. et al. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int 2013; 93: 448-452.
30 Glorieux FH, Devogelaer JP, Durigova M. et al. BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial. J Bone Miner Res 2017; 32: 1496-1504.
31 Chan JK, Gotherstrom C. Prenatal transplantation of mesenchymal stem cells to treat osteogenesis imperfecta. Front Pharmacol 2014; 05: 223.
32 Hoyer-Kuhn H, Semler O, Stark C, Struebing N, Goebel O, Schoenau E. A specialized rehabilitation approach improves mobility in children with osteogenesis imperfecta. J Musculoskelet Neuronal Interact 2014; 14: 445-453.
33 Mueller B, Engelbert R, Baratta-Ziska F. et al. Consensus statement on physical rehabilitation in children and adolescents with osteogenesis imperfecta. Orphanet Journal of Rare Diseases 2018; 13: 158.
34 Wirth T. [Osteogenesis imperfecta]. Orthopade 2012; 41: 773-782 quiz 83-84..
35 Ruck J, Dahan-Oliel N, Montpetit K, Rauch F, Fassier F. Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year. J Child Orthop 2011; 05: 217-224.
36 Ramaswamy R, Kosashvili Y, Cameron H. Bilateral total hip replacement in osteogenesis imperfecta with hyperplastic callus. J Bone Joint Surg Br 2009; 91: 812-814.